Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...

Cerebellar ataxia is a neurological disorder of the ... It can have various causes, which are often genetic. However, strokes or tumors can also be triggers. A research team led by Professor ...

Paraesthesias, dysarthria and ataxia were commonly reported adverse effects in all ... DBS has become the most common surgical procedure for ET and was approved by the Food and Drug Administration ...

Cerebellar ataxias are a group of genetic and non-genetic disorders that currently have no effective treatment. Despite their different causes, all forms of ataxia share a common set of motor ...

Ataxia is caused by damage in cerebellum, leading to poor muscle control. Know the causes and types of ataxia that can lead to other health complications. Ataxia is a condition caused by damage in ...

A team of researchers from the Universitat Politècnica de València (UPV) and the French National Centre for Scientific Research (CNRS) has developed the world's most advanced software to study ...

A class of drugs commonly used to treat movement disorders like Parkinson’s disease and restless leg syndrome is pushing people into risky sexual behavior. Patients taking dopamine agonists say ...

Multi-epitope immunopurifications of huntingtin (HTT) from vulnerable brain regions of Huntington’s disease (HD) models ...

That study will be out soon, the last patient has been seen. The other drug in the pipeline, which is the next closest, is vatiquinone. It had two trials in FA, one in adults and one in children.